Publications – Page 7 – ISDB – International Society of Drug Bulletins

Trilogue Meetings: increase transparency to level the playing field (March 2016)

March 1, 2016 Press releases, Publications

31 March 2016 Trilogues are meetings held between representatives of the European Parliament, Council and European Commission to discuss policy and legislative proposals. In a joint submission to a public consultation by the European Ombudsman, HAI, ISDB, the Medicines in Europe Forum and the Nordic Cochrane Centre recommend the establishment of a register of Trilogue documents, in order to level the playing field in favour of the public interest.

Why You Should Be Concerned About TTIP and Access to Medicines (February 2016)

February 1, 2016 Press releases, Publications

18 February 2016 Joint Position Statement by HAI, The Commons Network and Public Citizen. Summary Both the European Union (EU) and the United States (US) are confronted with increasingly high medicine prices. European Member States are facing a looming access to medicines crisis as they struggle to afford new, patented, high-priced medicines. The Transatlantic Trade and Investment Partnership Agreement (TTIP), now under negotiation, could hamper needed changes towards affordability, needs-driven innovation and alternative incentive structures.

EU Clinical Trials Regulation: EMA steers away from transparency by misinterpreting exception provisions

February 18, 2015 Press releases, Publications

Joint response to an EMA public consultation

The European Medicines Agency (EMA) must stay true to the Clinical Trials Regulation: non-disclosure has to remain the exception, not become the norm!

Press release and joint response attached as PDF:

European Medicines Agency (EMA) softens its conflict of interest policy: Does this further open the door to undue influence instead of closing it?

November 28, 2014 Press releases, Publications

28 November 2014

Joint Press Release

At the end of November 2014, the European Medicines Agency has announced the adoption of a “more balanced approach to handling conflicts of interests” to become effective on 30 January 2015. In reality, this revised EMA COI policy relaxes EMA’s position in relation to the conflicts of interest of experts with pharmaceutical companies. The evaluation of the efficacy and harms of medicines must be free from undue influence and be based on scientific data, so that the Agency’s work can benefit public health. The Agency’s integrity is at stake